Galegenimab, a relatively developed agent, is sparking considerable buzz within the oncology community. This innovative substance functions as an antagonist of TIGIT, a checkpoint protein, which plays a https://bookmarks-hit.com/story25962429/galegenimab-a-emerging-possibility-in-tumor-therapy